Plasma microRNA-586 is a new biomarker for acute graft-versus-host disease
- 9 June 2015
- journal article
- clinical trial
- Published by Springer Nature in Annals of Hematology
- Vol. 94 (9) , 1505-1514
Abstract
Acute graft-versus-host disease (aGVHD) is one of the major causes of morbidity and mortality in patients receiving allogeneic hematopoietic cell transplantation (allo-HSCT). MicroRNAs (miRs) were found to have the potential to be the new biomarkers of aGVHD. In this study, we collected samples from 98 patients who underwent allo-HSCT; 63 patients developed aGVHD, and 35 patients did not. Plasma samples were collected at three time points (before aGVHD, at the onset of aGVHD, and after aGVHD) from 52 patients, and the miR-586 expression level was detected by quantitative real-time PCR. We found that the plasma miR-586 level was decreased at the onset of grade I–II aGVHD (P = 0.074). In contrast, when infections were detected, plasma miR-586 level was increased. Moreover, we detected the miR-586 expression level in patients who had infections but did not have aGVHD, and we found that miR-586 was upregulated (P = 0.005). We also compared the plasma miR-586 level at day 7 after transplantation between aGVHD patients and control patients. In the aGVHD group, there was a considerably higher miR-586 expression in comparison with the non-aGVHD group (P < 0.05). A more significant difference between the two groups was found when the patients with infections were excluded (P = 0.004). Furthermore, receive operating characteristic (ROC) analysis indicated that a higher expression level of miR-586 at day 7 could predict impending aGVHD. The optimal cutoff value of miR-586 to predict aGVHD was 2200 copies/μL with a sensitivity of 87.5 % and specificity of 55.0 %, and the area under the curve (AUC) was 0.739 (95 % CI 0.598–0.880, P = 0.004). Our study suggests that miR-586 might participate in the occurrence of aGVHD and could be a putative target for novel aGVHD therapy. The plasma level of miR-586 at day 7 after allo-HSCT would be a potential biomarker for predicting the occurrence of aGVHD.Keywords
This publication has 39 references indexed in Scilit:
- Identification of a set of miRNAs differentially expressed in transiently TIA-depleted HeLa cells by genome-wide profilingBMC Molecular Biology, 2013
- MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteinsNature Cell Biology, 2011
- Frequency of CD4+CD25hiFOXP3+ Regulatory T Cells Has Diagnostic and Prognostic Value as a Biomarker for Acute Graft-versus-Host-DiseaseTransplantation and Cellular Therapy, 2010
- Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living CellsJournal of Biological Chemistry, 2010
- Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humansEuropean Heart Journal, 2010
- Graft-versus-host diseaseThe Lancet, 2009
- Most mammalian mRNAs are conserved targets of microRNAsGenome Research, 2008
- Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseasesCell Research, 2008
- Circulating microRNAs as stable blood-based markers for cancer detectionProceedings of the National Academy of Sciences, 2008
- MicroRNA-155 is induced during the macrophage inflammatory responseProceedings of the National Academy of Sciences, 2007